Genetic score may spot pancreatic cancer risk early
NCT ID NCT07516392
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a polygenic risk score—a measure based on many small genetic variations—can help predict who might develop pancreatic ductal adenocarcinoma (PDAC). Researchers will compare the genetic profiles of about 1,140 people with and without the disease. The goal is to improve risk prediction and support earlier detection of this aggressive cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Heating the body to fight pancreatic cancer: a new trial tests Whole-Body hyperthermia
- New drug combo targets Hard-to-Treat cancers with specific gene deletion
- Blood filter aims to suck cancer cells out of patients with advanced tumors
- Blood marker may forecast deadly pancreatic surgery complications
- New drug DA-3501 takes on tough cancers in first human trial
- Bile drain before pancreatic surgery: help or hindrance?